Chronic pain is not simply a physical experience — it reshapes the way your nervous system processes every sensation, and over time it can erode sleep, mood, mobility, and the ability to find pleasure in things that once mattered. In 2023, an estimated 24.3% of U.S. adults had chronic pain, and 8.5% experienced high-impact chronic pain that frequently limited life or work activities (Lucas & Sohi, 2024). For a significant portion of those patients, standard interventions — opioids, NSAIDs, nerve blocks, physical therapy — have offered only partial relief or have become difficult to sustain long-term. IV ketamine, administered in a medically supervised setting at Allevate Health in Middletown Township, NJ, represents a different approach to pain that is increasingly supported by clinical evidence.
How Chronic Pain Becomes Entrenched in the Nervous System
Acute pain is protective — a signal that something needs attention. Chronic pain, by contrast, is often no longer serving that protective function. Through a process called central sensitization, the central nervous system becomes abnormally amplified in its response to input, firing pain signals in the absence of ongoing tissue damage or in response to stimuli that would not ordinarily be painful (Latremoliere & Woolf, 2009). The NMDA (N-methyl-D-aspartate) receptor plays a central role in this process of central sensitization, essentially functioning as a molecular switch that keeps the pain pathway in an activated state.
This is where ketamine’s mechanism becomes clinically relevant. Ketamine is a potent NMDA receptor antagonist — it blocks the receptor involved in central sensitization and, in doing so, may help interrupt the pathological pain cycle that standard analgesics cannot always reach (Cohen et al., 2018). In a medically supervised infusion setting, subanesthetic doses of IV ketamine have been used to treat a range of chronic pain conditions including complex regional pain syndrome (CRPS), fibromyalgia, neuropathic pain, and refractory pain following spinal injury. Discuss with your provider whether IV ketamine is appropriate for your specific pain condition.
Conditions That May Respond to IV Ketamine
Not all chronic pain is the same, and not every pain condition responds equally to ketamine. Clinical evidence is strongest for conditions with a significant central sensitization component:
Complex Regional Pain Syndrome (CRPS): CRPS is characterized by disproportionate, often debilitating pain — frequently following an injury or surgery — that spreads beyond the initial site and is accompanied by changes in skin color, temperature, and swelling. Consensus guidelines on IV ketamine for chronic pain found moderate evidence supporting ketamine infusions for CRPS, while also emphasizing that evidence varies by condition and dose range (Cohen et al., 2018).
Fibromyalgia: The widespread musculoskeletal pain, fatigue, and cognitive difficulties of fibromyalgia are closely linked to central sensitization mechanisms. IV ketamine has shown potential in fibromyalgia studies, though long-term durability remains less certain and larger controlled studies are still needed (Pastrak et al., 2021).
Neuropathic pain: Neuropathic pain from diabetes, chemotherapy, postherpetic neuralgia, or other causes creates chronic burning, shooting, or stabbing sensations that are often poorly responsive to opioids. Ketamine’s NMDA antagonism targets a mechanism that is central to neuropathic pain generation.
Refractory pain syndromes: For patients whose pain has not responded adequately to multiple prior treatments, IV ketamine may be considered within a comprehensive pain management plan. Results vary by individual, and a thorough evaluation is required.
The IV Ketamine Infusion Experience at Allevate Health Middletown
At Allevate Health Middletown, IV ketamine treatment for chronic pain is administered intravenously in a medically supervised setting, with monitoring of vital signs throughout. Dosing protocols for chronic pain often differ from psychiatric indications — infusion duration and concentration are tailored to each patient’s clinical profile.
Before your first infusion, a complimentary consultation reviews your full pain history, prior treatments, current medications, and medical background. Our clinicians identify any contraindications — including uncontrolled hypertension, active psychosis, or certain cardiovascular conditions — and design your treatment plan accordingly. The number of infusions in an initial series for chronic pain varies by patient, condition, and response, with maintenance options discussed based on your progress. Learn more about ketamine infusions for chronic pain at Allevate Health.
Barriers to Care
The absence of insurance coverage for IV ketamine in chronic pain remains a significant barrier for many patients in Monmouth County and across New Jersey. Unlike SPRAVATO® for treatment-resistant depression, IV ketamine for pain management is not FDA-approved for that indication and is therefore typically not covered by commercial insurance as an established benefit. At Allevate Health, we discuss the financial picture transparently during your consultation so you can make a realistic, informed decision. Some patients who have exhausted covered options and continue to experience high-impact pain find that the quality-of-life improvement justifies the cost; others explore financing or supplemental coverage options.
Coordination with existing pain management providers can be complex when adding a new modality to an established care plan. We encourage you to inform your current treating physicians — whether a neurologist, rheumatologist, or pain specialist — before beginning ketamine infusions. Our clinical team can communicate with your care team and help ensure that the addition of ketamine to your regimen is medically sound. Discuss any medication adjustments, particularly opioids or benzodiazepines, only with your licensed providers.
Realistic Expectations and the Research Landscape
Clinical evidence for ketamine in chronic pain is growing but remains more heterogeneous than the psychiatric literature. Effects after an initial series can range from short-term relief to longer benefit in select patients, with wide individual variation — some patients experience sustained relief and require only periodic maintenance, while others find the benefit shorter-lived and need more frequent treatments to maintain function.
A systematic review examining IV ketamine across multiple chronic pain conditions found significant short-term analgesic benefit in patients with refractory chronic pain, while noting that larger studies with longer follow-up are needed to better determine optimal protocols and durability (Orhurhu et al., 2019). Results vary by individual. Our goal is not to create an expectation of permanent cure, but to help you find a measurable improvement in pain and function that allows you to engage more fully in your daily life, your rehabilitation, and the relationships that matter.
Taking the Next Step
If you are living with chronic pain in Middletown Township, Monmouth County, or the surrounding NJ Shore area and standard treatments have not brought adequate relief, a conversation with our clinical team may open a door you did not know was available. Call Allevate Health Middletown at 848-345-5831 or visit our Middletown Township location page to schedule your complimentary consultation. Our team will review your history and give you an honest assessment of whether IV ketamine belongs in your care plan. You can also contact us online to get started.
Frequently Asked Questions
Is IV ketamine for chronic pain FDA-approved?
IV ketamine is FDA-approved as an anesthetic, and its use for chronic pain conditions is considered off-label (DailyMed, 2026). This means it is used based on clinical evidence and physician judgment rather than a specific FDA indication for pain. Off-label use under physician supervision is a well-established and legal practice in medicine. Learn more about IV ketamine at Allevate Health.
How long does pain relief typically last after a ketamine infusion series?
Duration varies widely by individual, pain condition, and the number of infusions administered. Some patients experience relief for weeks to months; others see shorter durations and benefit from maintenance infusions. Realistic expectations are discussed in detail during your consultation.
Can I continue my current pain medications during ketamine treatment?
Many patients continue their existing pain regimens during ketamine infusion series, but certain medications — including high-dose opioids and benzodiazepines — may require adjustment. Your full medication list is reviewed before treatment begins. Never change your pain medications without consulting your licensed provider.
What does the infusion feel like?
During the infusion, you may experience mild dissociative effects — a floating sensation, altered perception of time, or dreamlike thoughts. These are transient, resolve as the infusion ends, and are managed by our clinical team. You will be monitored throughout the session.
Does Allevate Health treat pain alongside depression?
Yes. Many patients with chronic pain also experience comorbid depression or anxiety. Allevate Health offers treatment options for both chronic pain and mental health conditions, and your clinician can help determine which option is appropriate for each part of your clinical picture. SPRAVATO® is FDA-approved for treatment-resistant depression, while IV ketamine for chronic pain is used off-label.
Key Takeaways
In 2023, an estimated 24.3% of U.S. adults had chronic pain, and 8.5% experienced high-impact chronic pain that frequently limited life or work activities (Lucas & Sohi, 2024).
Chronic pain often involves central sensitization — an NMDA-receptor-related process — which is specifically targeted by IV ketamine’s mechanism of action.
Clinical evidence supports IV ketamine most strongly for conditions such as CRPS, while evidence for other chronic pain conditions varies and results differ by individual (Cohen et al., 2018).
IV ketamine for chronic pain is off-label, typically not covered by insurance, and requires thorough medical evaluation for candidacy.
Allevate Health Middletown offers IV ketamine in a medically supervised setting with a complimentary consultation.
References
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., Lubenow, T. R., & Hooten, W. M. (2018). Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Regional Anesthesia and Pain Medicine, 43(5), 521–546. https://doi.org/10.1097/AAP.0000000000000808
Latremoliere, A., & Woolf, C. J. (2009). Central sensitization: A generator of pain hypersensitivity by central neural plasticity. The Journal of Pain, 10(9), 895–926. https://doi.org/10.1016/j.jpain.2009.06.012
Lucas, J. W., & Sohi, I. (2024). Chronic pain and high-impact chronic pain in U.S. adults, 2023. National Center for Health Statistics Data Brief, No. 518. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/products/databriefs/db518.htm
Orhurhu, V., Orhurhu, M. S., Bhatia, A., & Cohen, S. P. (2019). Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesthesia & Analgesia, 129(1), 241–254. https://doi.org/10.1213/ANE.0000000000004185
Pastrak, M., Abd-Elsayed, A., Ma, F., Vrooman, B., & Visnjevac, O. (2021). Systematic review of the use of intravenous ketamine for fibromyalgia. The Ochsner Journal, 21(4), 387–394. https://doi.org/10.31486/toj.21.0038
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.